A Phase 2 interventional study of Apixaban and Apixaban in Acute Coronary Syndrome (ACS), sponsored by Bristol-Myers Squibb. Completed at 151 sites in 14 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2015-12-30.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 265 studies in Acute Coronary Syndrome with a site in United States — 14 open to participants now, 21 under way, 2 of them phase 3. Acute Coronary Syndrome · United States.
Among the 265 studies in Acute Coronary Syndrome with a site in United States, this one is the 39th largest by enrollment of the 186 interventional ones that give a count, is one of 18 that started in 2006, is one of 29 in phase 2, and was the 15th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
Browse Acute Coronary Syndrome studies →14 of the 265 studies in Acute Coronary Syndrome with a site in United States are open now. Recruiting first, the newest first:
Teleflex · Sites in United States, France, Latvia and 1 more country
Ages 18–80
Shanghai CureGene Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–55 · Healthy volunteers
Columbia University · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of South Florida · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
265 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 36 · Phase 3 41 · Phase 4 27
First in 2001; this study’s year is marked. 18 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,741 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 150 across the 186 interventional studies, 500 across the 79 observational. Of the 214 that completed or were terminated, 97 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 265 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 4 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Acute Coronary Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05918861Phase 3DalCor PharmaceuticalsEffect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | 2027-08 |
| NCT06481943SB Technology, Inc.A Prospective Research Investigation of Ischemia Using MCG | 2026-12 |
| NCT05412927Angel Medical SystemsAngelMed Guardian® System PMA Post Approval Study | 2026-12 |
| NCT04496687SCAD AllianceInternational Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry | 2026-12-31 |
| NCT06927739AbcentraFocused Orticumab Research for Treating Inflammation in Coronary Arteries | 2027-02-08 |
Add all 7 to your calendar (.ics) → With an account.
Among the 265 studies in Acute Coronary Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.
Key Inclusion Criteria:
Key Exclusion Criteria:
Drug: Apixaban
Drug: Apixaban
Drug: Placebo
Drug: Apixaban
Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses
Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The primary outcome is based on data for the placebo and 2 apixaban low-dose groups (2.5 mg BID and 10 mg QD) combined across Phase A and Phase B. The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups (10mg BID, 20mg QD) and the resulting lower duration of exposure for these groups.
Time frame: From first dose of study drug (Day 1) to last dose plus 2 days, up to Year 2 of the Study
Number of Participants With a Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants
Events were adjudicated by the Clinical Events Committee (CEC). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B.
Time frame: Randomization to 182 days after randomization (183 days)
Event Rate for Adjudicated All Bleeding Events During the Treatment Period - Treated Participants With Placebo or Apixaban Low Doses
Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events includes major bleeding, clinically relevant non-major bleeding and minor bleeding. Treatment Period refers to the period from first dose through 2 days, or through 30 days for Serious Adverse Event (SAE) tabulations, after discontinuation of study drug. Data in this outcome are combined across Phase A and Phase B.
Time frame: first dose (Day 1) to last dose plus 2 days (or for SAEs, plus 30 days), up to Year 2 of the Study
Number of Participants With a Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants
Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B
Time frame: Day of randomization to 182 days after day of randomization (183 days)
Event Rate of Confirmed Adjudicated Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the Clinical Events Committee. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%).
Time frame: from first dose (Day 1) to last dose plus 2 days, up to Year 2 of the Study
Number of Participants With Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B
Phase B Adjusted Intended Treatment Period=day of randomization and ends on termination date of high dose apixaban, 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure.
Time frame: Day of randomization and ends on high dose termination date, 1-Oct-2007
Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Phase B Adjusted Treatment Period- Treated Participants Randomized in Phase B
Bleeding was assessed using ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups and the lower duration of exposure. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group).
Time frame: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
Event Rate for Adjudicated All Bleeding Events During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events included major bleeding, clinically relevant non-major bleeding and minor bleeding. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group).
Time frame: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
Number of Participants With Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B
Phase B Adjusted Intended Treatment Period=day of randomization and ends on 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure.
Time frame: Day of randomization up to high dose termination, 1-Oct-2007
Event Rate of Confirmed Adjudicated Major Bleeding During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%).
Time frame: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Milestone | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD | Apixaban 10mg BID | Apixaban 20 mg QD |
|---|---|---|---|---|---|
| Started | 184 | 179 | 184 | 0 | 0 |
| Completed | 130 | 140 | 149 | 0 | 0 |
| Not completed | 54 | 39 | 35 | 0 | 0 |
| Withdrew: Adverse event | 19 | 14 | 17 | 0 | 0 |
| Withdrew: Withdrawal by subject | 20 | 12 | 13 | 0 | 0 |
| Withdrew: Death | 3 | 4 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 4 | 2 | 0 | 0 |
| Withdrew: Poor/non-compliance | 3 | 2 | 1 | 0 | 0 |
| Withdrew: No longer meets criteria | 4 | 3 | 2 | 0 | 0 |
| Withdrew: Administrative reason (arm terminated) | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD | Apixaban 10mg BID | Apixaban 20 mg QD |
|---|---|---|---|---|---|
| Started | 427 | 138 | 134 | 248 | 221 |
| Start of phase b to high dose terminated | 368 | 120 | 110 | 248 | 221 |
| Completed | 333 | 105 | 94 | 15 | 13 |
| Not completed | 94 | 33 | 40 | 233 | 208 |
| Withdrew: Adverse event | 34 | 9 | 12 | 23 | 19 |
| Withdrew: Withdrawal by subject | 35 | 14 | 19 | 15 | 19 |
| Withdrew: Death | 5 | 3 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 5 | 2 | 3 | 2 | 3 |
| Withdrew: Poor/non-compliance | 3 | 1 | 3 | 0 | 0 |
| Withdrew: No longer meets criteria | 9 | 3 | 2 | 0 | 2 |
| Withdrew: Administrative reason by sponsor | 2 | 1 | 0 | 193 | 164 |
| Withdrew: Non-specified | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD | Apixaban 10mg BID | Apixaban 20 mg QD |
|---|---|---|---|---|---|
| Started | 163 | 162 | 174 | 0 | 0 |
| Completed | 158 | 156 | 172 | 0 | 0 |
| Not completed | 5 | 6 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 5 | 5 | 2 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 |
| Milestone | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD | Apixaban 10mg BID | Apixaban 20 mg QD |
|---|---|---|---|---|---|
| Started | 383 | 123 | 119 | 222 | 201 |
| Completed | 380 | 123 | 117 | 217 | 199 |
| Not completed | 3 | 0 | 2 | 5 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 | 2 | 1 | 1 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Missing end of study status | 1 | 0 | 0 | 2 | 0 |
Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The primary outcome is based on data for the placebo and 2 apixaban low-dose groups (2.5 mg BID and 10 mg QD) combined across Phase A and Phase B. The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups (10mg BID, 20mg QD) and the resulting lower duration of exposure for these groups.
| percentage of participants | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD |
|---|---|---|---|
| Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses | 3.0 (1.8 to 4.7) | 5.7 (3.4 to 8.9) | 7.9 (5.2 to 11.5) |
Events were adjudicated by the Clinical Events Committee (CEC). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B.
| participants | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD |
|---|---|---|---|
| Number of Participants With a Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants | 53 | 24 | 19 |
Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events includes major bleeding, clinically relevant non-major bleeding and minor bleeding. Treatment Period refers to the period from first dose through 2 days, or through 30 days for Serious Adverse Event (SAE) tabulations, after discontinuation of study drug. Data in this outcome are combined across Phase A and Phase B.
| percentage of participants | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD |
|---|---|---|---|
| Event Rate for Adjudicated All Bleeding Events During the Treatment Period - Treated Participants With Placebo or Apixaban Low Doses | 10.5 (8.2 to 13.3) | 20.6 (16.3 to 25.5) | 22.5 (18.0 to 27.6) |
Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B
| participants | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD |
|---|---|---|---|
| Number of Participants With a Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants | 54 | 24 | 20 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the Clinical Events Committee. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%).
| percentage of participants | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD |
|---|---|---|---|
| Event Rate of Confirmed Adjudicated Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses | 0.8 (0.3 to 1.9) | 1.6 (0.5 to 3.7) | 1.9 (0.7 to 4.1) |
Phase B Adjusted Intended Treatment Period=day of randomization and ends on termination date of high dose apixaban, 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure.
| participants | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD | Apixaban 10mg BID | Apixaban 20 mg QD |
|---|---|---|---|---|---|
| Number of Participants With Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B | 16 | 6 | 4 | 8 | 7 |
Bleeding was assessed using ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups and the lower duration of exposure. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group).
| percentage of participants | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD | Apixaban 10mg BID | Apixaban 20 mg QD |
|---|---|---|---|---|---|
| Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Phase B Adjusted Treatment Period- Treated Participants Randomized in Phase B | 0.8 (0.2 to 2.4) | 5.0 (1.9 to 10.7) | 5.6 (2.1 to 11.7) | 7.8 (4.8 to 11.9) | 7.3 (4.3 to 11.6) |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events included major bleeding, clinically relevant non-major bleeding and minor bleeding. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group).
| percentage of participants | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD | Apixaban 10mg BID | Apixaban 20 mg QD |
|---|---|---|---|---|---|
| Event Rate for Adjudicated All Bleeding Events During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B | 6.1 (3.8 to 9.1) | 15.1 (9.2 to 22.8) | 17.6 (10.9 to 26.1) | 24.2 (18.9 to 30.1) | 23.9 (18.4 to 30.1) |
Phase B Adjusted Intended Treatment Period=day of randomization and ends on 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure.
| participants | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD | Apixaban 10mg BID | Apixaban 20 mg QD |
|---|---|---|---|---|---|
| Number of Participants With Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B | 16 | 6 | 4 | 8 | 7 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%).
| percentage of participants | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD | Apixaban 10mg BID | Apixaban 20 mg QD |
|---|---|---|---|---|---|
| Event Rate of Confirmed Adjudicated Major Bleeding During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B | 0.0 (0.0 to 1.0) | 0.8 (0.0 to 4.6) | 0.0 (0.0 to 3.4) | 2.9 (1.2 to 5.8) | 4.1 (1.9 to 7.7) |
Collected over Day 1 up to 30 days post last dose of study drug, up to approximately 2 years: A+B treatment groups. March 2007 up to 30 days post last dose in October 2007 (termination of high doses), are presented in Phase B Treatment groups.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase A+B Apixaban 10mg QD | — | 72/315 (22.9%) | 122/315 (38.7%) |
| Phase A+B Apixaban 2.5mg BID | — | 73/315 (23.2%) | 101/315 (32.1%) |
| Phase A+B Placebo | — | 125/599 (20.9%) | 175/599 (29.2%) |
| Phase B Apixaban 10mg BID | — | 55/244 (22.5%) | 84/244 (34.4%) |
| Phase B Apixaban 10mg QD | — | 22/108 (20.4%) | 30/108 (27.8%) |
| Phase B Apixaban 20mg QD | — | 36/218 (16.5%) | 67/218 (30.7%) |
| Phase B Apixaban 2.5mg BID | — | 19/119 (16%) | 22/119 (18.5%) |
| Phase B Placebo | — | 56/362 (15.5%) | 80/362 (22.1%) |
| Event | Phase A+B Apixaban 10mg QD | Phase A+B Apixaban 2.5mg BID | Phase A+B Placebo | Phase B Apixaban 10mg BID | Phase B Apixaban 10mg QD | Phase B Apixaban 20mg QD | Phase B Apixaban 2.5mg BID | Phase B Placebo |
|---|---|---|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 11/315 | 8/315 | 24/599 | 3/244 | 3/108 | 1/218 | 1/119 | 12/362 |
| Chest painGeneral disorders | 7/315 | 6/315 | 13/599 | 7/244 | 2/108 | 6/218 | 1/119 | 8/362 |
| Non-cardiac chest painGeneral disorders | 6/315 | 2/315 | 4/599 | 5/244 | 3/108 | 1/218 | 0/119 | 2/362 |
| IschaemiaVascular disorders | 8/315 | 4/315 | 12/599 | 4/244 | 2/108 | 6/218 | 1/119 | 5/362 |
| Angina pectorisCardiac disorders | 6/315 | 8/315 | 11/599 | 5/244 | 1/108 | 3/218 | 2/119 | 4/362 |
| Angina unstableCardiac disorders | 5/315 | 6/315 | 14/599 | 5/244 | 2/108 | 3/218 | 0/119 | 6/362 |
| PyrexiaGeneral disorders | 0/315 | 2/315 | 0/599 | 0/244 | 0/108 | 0/218 | 2/119 | 0/362 |
| Acute myocardial infarctionCardiac disorders | 1/315 | 4/315 | 4/599 | 3/244 | 0/108 | 1/218 | 1/119 | 2/362 |
| Atrial fibrillationCardiac disorders | 4/315 | 3/315 | 3/599 | 0/244 | 1/108 | 0/218 | 1/119 | 2/362 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/315 | 1/315 | 1/599 | 3/244 | 0/108 | 0/218 | 1/119 | 0/362 |
| Event | Phase A+B Apixaban 10mg QD | Phase A+B Apixaban 2.5mg BID | Phase A+B Placebo | Phase B Apixaban 10mg BID | Phase B Apixaban 10mg QD | Phase B Apixaban 20mg QD | Phase B Apixaban 2.5mg BID | Phase B Placebo |
|---|---|---|---|---|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 24/315 | 18/315 | 18/599 | 16/244 | 5/108 | 25/218 | 4/119 | 2/362 |
| Chest painGeneral disorders | 27/315 | 21/315 | 52/599 | 19/244 | 9/108 | 14/218 | 4/119 | 24/362 |
| ContusionInjury, poisoning and procedural complications | 26/315 | 20/315 | 20/599 | 12/244 | 4/108 | 10/218 | 4/119 | 10/362 |
| HeadacheNervous system disorders | 25/315 | 17/315 | 30/599 | 15/244 | 2/108 | 6/218 | 0/119 | 12/362 |
| FatigueGeneral disorders | 8/315 | 13/315 | 26/599 | 16/244 | 1/108 | 6/218 | 4/119 | 14/362 |
| Gingival bleedingGastrointestinal disorders | 11/315 | 10/315 | 9/599 | 15/244 | 2/108 | 8/218 | 4/119 | 4/362 |
| Angina pectorisCardiac disorders | 19/315 | 18/315 | 31/599 | 10/244 | 5/108 | 11/218 | 3/119 | 12/362 |
| DizzinessNervous system disorders | 18/315 | 15/315 | 35/599 | 10/244 | 4/108 | 9/218 | 3/119 | 16/362 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 16/315 | 13/315 | 20/599 | 3/244 | 6/108 | 4/218 | 4/119 | 10/362 |
| HaematomaVascular disorders | 16/315 | 11/315 | 10/599 | 9/244 | 5/108 | 9/218 | 4/119 | 5/362 |
All randomized participants were summarized.
| Age, Continuous(years) | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD | Apixaban 10mg BID | Apixaban 20 mg QD | Total |
|---|---|---|---|---|---|---|
| Mean | 60.5 ± 11.25 | 61.1 ± 11.64 | 60.7 ± 11.35 | 60.3 ± 11.00 | 60.9 ± 11.95 | 60.7 ± 11.38 |
| Age, Customized(participants) | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD | Apixaban 10mg BID | Apixaban 20 mg QD | Total |
|---|---|---|---|---|---|---|
| Less than (<) 65 years | 374 | 187 | 197 | 165 | 132 | 1055 |
| Greater than, equal to 65 and < 75 years | 170 | 85 | 82 | 53 | 57 | 447 |
| Greater than (>) 75 years | 67 | 45 | 39 | 30 | 32 | 213 |
| Sex: Female, Male(Participants) | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD | Apixaban 10mg BID | Apixaban 20 mg QD | Total |
|---|---|---|---|---|---|---|
| Female | 157 | 75 | 86 | 45 | 50 | 413 |
| Male | 454 | 242 | 232 | 203 | 171 | 1302 |
| Region of Enrollment(participants) | Placebo | Apixaban 2.5mg BID | Apixaban 10mg QD | Apixaban 10mg BID | Apixaban 20 mg QD | Total |
|---|---|---|---|---|---|---|
| Russian Federation | 156 | 93 | 82 | 59 | 52 | 442 |
| United States | 69 | 40 | 44 | 24 | 14 | 191 |
| United Kingdom | 15 | 7 | 9 | 5 | 5 | 41 |
| Spain | 36 | 11 | 16 | 17 | 19 | 99 |
| Canada | 81 | 47 | 44 | 26 | 21 | 219 |
| Austria | 4 | 2 | 2 | 4 | 2 | 14 |
| Sweden | 42 | 21 | 24 | 12 | 12 | 111 |
| Belgium | 20 | 11 | 9 | 10 | 12 | 62 |
| Poland | 61 | 21 | 19 | 34 | 31 | 166 |
| Denmark | 16 | 14 | 15 | 5 | 4 | 54 |
| Israel | 55 | 29 | 32 | 26 | 21 | 163 |
| France | 21 | 9 | 8 | 8 | 10 | 56 |
| Germany | 34 | 12 | 14 | 17 | 18 | 95 |
| Italy | 1 | 0 | 0 | 1 | 0 | 2 |
Showing the first 100 of 151 sites across 14 countries. Choose a country and city above to see the rest.
The record gives a start of May 2006, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 7 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban